Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Denver, Colorado

This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7459
Shown on this page
12
Current sort
Recently updated
Location scope
Denver, CO
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Denver, Colorado. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 733–744 of 7,459 matching trials in Denver, CO.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Completed No phase listed Observational

Mobilization and Outcomes After Venous Closure

NCT07246902
View directory record Official record
Conditions
Venous Vascular Closure, Electrophysiology Study
Interventions
MYNX CONTROLTM VENOUS Vascular Closure Device
Device
Lead sponsor
Cordis US Corp.
Industry
Eligibility
Not listed
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Active, not recruiting Phase 3 Interventional

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

NCT04071457
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Daratumumab/rHuPH20
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
837
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Recruiting Phase 3 Interventional

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Completed Phase 4 Interventional Results available

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

NCT06229145
View directory record Official record
Conditions
Gout
Interventions
Pegloticase, Methotrexate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
74
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Completed Phase 3 Interventional

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

NCT02914535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
1,173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
57
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Recruiting No phase listed Observational

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728
View directory record Official record
Conditions
Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Interventions
Not listed
Lead sponsor
Exactech
Industry
Eligibility
21 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2031
U.S. locations
24
States / cities
Laguna Woods, California • Redwood City, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab, Placebo matched to fenebrutinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
43
States / cities
Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Terminated No phase listed Observational

Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)

NCT04502316
View directory record Official record
Conditions
Heart Failure
Interventions
Barostim™ System
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
Not listed
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Recruiting Phase 2 Interventional

Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia

NCT06098833
View directory record Official record
Conditions
Neonatal Encephalopathy
Interventions
Sildenafil, Ora-Blend
Drug
Lead sponsor
Pia Wintermark
Other
Eligibility
0 Minutes to 48 Hours
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Active, not recruiting Phase 3 Interventional

Cisplatin Disposition and Kidney Injury

NCT03817970
View directory record Official record
Conditions
Nephrotoxicity
Interventions
Granisetron, Ondansetron, Palonosetron
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Denver, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Enrolling by invitation Phase 2 Interventional

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

NCT06066580
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Sevasemten
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
24
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 15, 2026, 8:24 AM EST
Completed Phase 1Phase 2 Interventional

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

NCT04866134
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
ERAS-007, ERAS-601
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 15, 2026, 8:24 AM EST